OTC
0.03USD
0.00 (0.00%)
We have scored 4 news catalysts on Ventana Biotech, Inc. (VNTA) over the past 12 months. The biggest single-day move next to one of them came Oct 17, 2026, when VNTA closed +0.0%: “Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry”. Coverage across the window leans positive (average ticker sentiment +0.40). Most of the impact sits in sector healthcare and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
87K
P/E
—
EPS
—
Beta
-3.53
52W range
0.0316-0.0849
Day range
0.03–0.03
Open
0.03
Prev close
0.03
Volume
50
Avg volume
311
Dividend
0.00
IPO
2009-09-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Ventana Biotech, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VNTA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions. Notably, Ventana holds proprietary rights to a medicated chewing gum formulation that integrates an extract of hoodia gordonii and 2-hydroxyoleic acid. This unique composition is intended for the management of obesity, hypertension, and various other metabolic disorders. Ventana is actively engaged in developing these appetite-suppressant chewing gums into distinct products: a lower-dosage version aimed at the over-the-counter market, and a higher-dosage variant slated for distribution via pharmacists. The lower-strength product is expected to be retailed in drugstores and health food establishments. Established in 1989, Ventana Biotech, Inc. operates from Butschwil, Switzerland. The company adopted its current name in October 2008, having previously been known as Personalica, Inc.
